Treatment Modification to Reduce Symptom Burden in Hemodialysis

The Rogosin Institute16 enrolled

Overview

Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

End Stage Renal Disease

Interventions

Treatment modificationOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * hemodialysis patient * transplant ineligible Exclusion Criteria: * dementia * unable to answer questionnaires for any reason

Locations (1)

The Rogosin Institute

New York, New York, United States

Outcomes

Primary Outcomes

Number of Participants Recruited, Consented, Randomized and Completed

Time frame: Each participant was assessed for 6 weeks; total recruitment period was 15 months

Secondary Outcomes

Symptom Burden

Number of symptoms in past week as measured by the Dialysis Symptom Index

Time frame: Baseline and 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.